ACE and chronic kidney disease: Previous studies demonstrated that using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could reduce the morbidity of cardiovascular events and mortality in chronic kidney disease (CKD) patients [2, 3].